7 Hills Pharma is at the forefront of developing innovative immunotherapy solutions, particularly through its lead molecules, alintegimod and 7HP935. Alintegimod is a first-in-class integrin-targeted agonist designed to enhance the effectiveness of immune checkpoint inhibitors, specifically in overcoming resistance to aPD-1 therapies in solid tumors. This orally-delivered small molecule selectively activates integrins LFA-1 and VLA-4, which are crucial for various steps in the cancer immunity cycle, including T cell recruitment, activation, and tumor targeting. Currently, alintegimod is undergoing a Phase Ib/IIa clinical trial, demonstrating its potential to improve treatment outcomes for patients with advanced solid tumors that are resistant to existing therapies.

In addition to alintegimod, 7HP935 represents another significant advancement in the company's pipeline, focusing on improving cell and gene therapies. This small molecule selectively activates the integrin VLA-4, which is vital for the successful engraftment of hematopoietic stem cells in the bone marrow. By potentially reducing the time to engraftment and minimizing complications associated with hematopoietic stem cell transplants, 7HP935 aims to enhance treatment efficacy for patients with acute leukemias and genetic disorders. Furthermore, its application in combination with umbilical cord blood transplants could address disparities in donor matching, offering a promising therapeutic option for diverse patient populations.

United States

7 Hills Pharma is a clinical-stage immunotherapy company developing a platform of novel, oral small molecules for the treatment of cancer and prevention of infectious diseases. Our compounds are first-in-concept allosteric integrin activators that leverage a unique mechanism of action to stabilize the cell-cell interactions required to mount an effective immune response. Our lead clinical candidate, 7HP349, is the only reported systemically safe immune stimulant that can activate both cellular and humoral immunity. 

7 Hills Pharma

Company Details